Prospective Evaluation of Thin-strut Biodegradable Polymer-coated Supralimus Grace Sirolimus-eluting Stents in an All-comers Patient Population

Investigator Initiated Study0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Patient aged 18 years or older
•2. Patient with symptomatic coronary artery disease
•3. Patient with a clinical indication for percutaneous coronary intervention (PCI) and stenting of at least one coronary lesion, visually confirmed on coronary angiography
•4. Only Supralimus Grace stent(s) is/are to be implanted into the coronary vasculature during the index procedure
•5. Patient provides signed informed consent for data release
•6. Patient willing to comply with protocol specified follow-up

•1. Patient with cardiogenic shock
•2. Patient who is pregnant or possibly pregnant
•3. Patients has a known hypersensitivity or contraindication to aspirin, clopidogrel, ticlopidine, heparin or any other anticoagulation / antiplatelet therapy required for PCI, cobalt chromium, sirolimus or contrast media
•4. Patient scheduled to undergo elective surgery within 12 months post-index PCI
•5. Patient who is currently participating in a clinical study of another drug or medical device and in whom assessment of the primary endpoint of that study has not been completed or clinically interferes with the endpoints of this clinical study

发起方

Investigator Initiated Study